Compare First Trust Cloud Computing ETF (SKYY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs TransMedics Group Inc — how do they compare? First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: First Trust Cloud Computing ETF is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and TransMedics Group Inc for 24 Days on average.
| SKYY | TMDX | |
|---|---|---|
Market Cap | $3.47B | $2.74B |
Volume | 176,159 | 949,331 |
52-Week High | $174.89 | $150.42 |
52-Week Low | $104.16 | $61.99 |
Typical Hold Time | 85 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY (First Trust Cloud Computing ETF) trades at $170.14, down 0.37% on the day but near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support and neutral oscillators. The ETF benefits from strong secular trends in cloud computing and AI adoption, with recent news highlighting institutional position adjustments and positive sector momentum.
The outlook remains positive given cloud computing's growth trajectory and AI infrastructure demand. Key risks include sector concentration and market volatility. Analyst sentiment is generally favorable, though valuation metrics are not provided in current data. The ETF's diversified exposure to cloud infrastructure positions it well for continued technology adoption trends.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
